Q-omics provides the consensus-scored MYO16-AS2 profile across patient tissues and cancer cell-line models. MYO16-AS2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MYO16-AS2 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, MYO16-AS2 RNA expression shows 7,481 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight UCS, PRAD, and UCEC as cancer lineages where MYO16-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO16-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO16-AS2 survival associations across molecular data types. MYO16-AS2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO16-AS2 RNA expression–survival associations across cancer types. High MYO16-AS2 expression shows unfavorable associations in UCS, HNSC, ACC, COAD, BLCA and STAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MYO16-AS2 RNA expression.
This table summarizes MYO16-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MYO16-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO16-AS2 shows higher tumor expression in PRAD. The PRAD box plot shows higher MYO16-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .042).
This table shows molecular features associated with MYO16-AS2 in patient tissues and cancer cell lines. In patient samples, MYO16-AS2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
